The insect peptide coprisin prevents Clostridium difficile-mediated acute inflammation and mucosal damage through selective antimicrobial activity

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 10, 2011, Pages 4850-4857

  Kang, Jin Ku ^a   Hwang, Jae Sam ^b   Nam, Hyo Jung ^a   Ahn, Keun Jae ^c   Seok, Heon ^d   Kim, Sung Kuk ^a   Yun, Eun Young ^b   Pothoulakis, Charalabos ^e   Lamont, John Thomas ^f   Kim, Ho ^a  

^a Daejin University   (South Korea)

^b National Institute of Animal Science   (South Korea)

^c Hallym University   (South Korea)

^d Jungwon University   (South Korea)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; CLINDAMYCIN; COPRISIN DERIVATIVE; INTERLEUKIN 6; KANAMYCIN; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL MEMBRANE; BACTERIAL SURVIVAL; BIFIDOBACTERIUM; BODY WEIGHT; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLONY FORMING UNIT; COMMENSAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG SYNTHESIS; ENTERITIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LACTOBACILLUS; MALE; MEMBRANE DAMAGE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH INJURY; SURVIVAL RATE;

AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; BEETLES; BIFIDOBACTERIUM; CELL MEMBRANE; CLOSTRIDIUM DIFFICILE; CYTOKINES; DRUG RESISTANCE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; INSECT PROTEINS; INTESTINAL MUCOSA; LACTOBACILLUS; MALE; MICE; MICROBIAL SENSITIVITY TESTS; OLIGOPEPTIDES;

EID: 80052846238     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00177-11     Document Type: Article

References (51)

1. Ackermann, G., B. Loffler, D. Adler, and A. C. Rodloff. 2004. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob. Agents Chemother. 48: 2280-2282.
2. Alfa, M. J., T. Du, and G. Beda. 1998. Survey of incidence of Clostridium difficile infection in Canadian hospitals and diagnostic approaches. J. Clin. Microbiol. 36:2076-2080.
3. Amit-Romach, E., Z. Uni, and R. Reifen. 2008. Therapeutic potential of two probiotics in inflammatory bowel disease as observed in the trinitrobenzene sulfonic acid model of colitis. Dis. Colon Rectum 51:1828-1836.
4. Anton, P. M., et al. 2004. Rifalazil treats and prevents relapse of Clostridium difficile-associated diarrhea in hamsters. Antimicrob. Agents Chemother. 48:3975-3979.
5. Aroutcheva, A., J. A. Simoes, S. Shott, and S. Faro. 2001. The inhibitory effect of clindamycin on Lactobacillus in vitro. Infect. Dis. Obstet. Gynecol. 9:239-244.
6. Brakhage, A. A., et al. 2004. Regulation of penicillin biosynthesis in filamentous fungi. Adv. Biochem. Eng. Biotechnol. 88:45-90.
7. Campopiano, D. J., et al. 2004. Structure-activity relationships in defensin dimers: a novel link between beta-defensin tertiary structure and antimicrobial activity. J. Biol. Chem. 279:48671-48679.
8. Chen, X., et al. 2008. A mouse model of Clostridium difficile-associated disease. Gastroenterology 135:1984-1992.
9. Elmer, G. W., C. M. Surawicz, and L. V. McFarland. 1996. Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA 275:870-876.
10. Fekety, R. 1997. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am. J. Gastroenterol. 92:739-750.
11. Hristova, K., M. E. Selsted, and S. H. White. 1997. Critical role of lipid composition in membrane permeabilization by rabbit neutrophil defensins. J. Biol. Chem. 272:24224-24233.
12. Reference Deleted.
13. Hwang, J.-S., et al. 22 October 2009, posting date. Isolation and characterization of a defensin-like peptide (coprisin) from the dung beetle, Copris tripartitus. Int. J. Pept. doi:10.1155/2009/136284.
14. Just, I., et al. 1995. Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature 375:500-503.
15. Kawasaki, S., T. Mimura, T. Satoh, K. Takeda, and Y. Niimura. 2006. Response of the microaerophilic Bifidobacterium species, B. boum and B. thermophilum, to oxygen. Appl. Environ. Microbiol. 72:6854-6858. (Pubitemid 44582936)
16. Kelly, C. P., and J. T. LaMont. 2008. Clostridium difficile - more difficult than ever. N. Engl. J. Med. 359:1932-1940.
17. Kelly, C. P., C. Pothoulakis, and J. T. LaMont. 1994. Clostridium difficile colitis. N. Engl. J. Med. 330:257-262.
18. Kim, H., et al. 2005. Clostridium difficile toxin A-induced colonocyte apoptosis involves p53-dependent p21(WAF1/CIP1) induction via p38 mitogen-activated protein kinase. Gastroenterology 129:1875-1888.
19. Kim, H., et al. 2005. Clostridium difficile toxin A regulates inducible cyclooxygenase- 2 and prostaglandin E2 synthesis in colonocytes via reactive oxygen species and activation of p38 MAPK. J. Biol. Chem. 280:21237-21245.
20. Kim, H., S. H. Rhee, C. Pothoulakis, and J. T. Lamont. 2007. Inflammation and apoptosis in Clostridium difficile enteritis is mediated by PGE2 upregulation of Fas ligand. Gastroenterology 133:875-886.
21. Kokkotou, E., et al. 2008. Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. Antimicrob. Agents Chemother. 52:1121-1126.
22. Kyne, L., R. J. Farrell, and C. P. Kelly. 2001. Clostridium difficile. Gastroenterol. Clin. North Am. 30:753-777, ix-x.
23. Lai, K. K., Z. S. Melvin, M. J. Menard, H. R. Kotilainen, and S. Baker. 1997. Clostridium difficile-associated diarrhea: epidemiology, risk factors, and infection control. Infect. Control Hosp. Epidemiol. 18:628-632.
24. Lamberty, M., et al. 1999. Insect immunity. Isolation from the lepidopteran Heliothis virescens of a novel insect defensin with potent antifungal activity. J. Biol. Chem. 274:9320-9326.
25. Lorian, V., and F. Fernandes. 1999. Electron microscopy studies of the bactericidal effects of quinupristin/dalfopristin on Staphylococcus aureus. J. Antimicrob. Chemother. 43:845.
26. McFarland, L. V., et al. 1995. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am. J. Gastroenterol. 90:439-448.
27. Reference Deleted.
28. Oozeer, R., et al. 2002. Lactobacillus casei is able to survive and initiate protein synthesis during its transit in the digestive tract of human floraassociated mice. Appl. Environ. Microbiol. 68:3570-3574.
29. Peláez, T., et al. 2008. Metronidazole resistance in Clostridium difficile is heterogeneous. J. Clin. Microbiol. 46:3028-3032.
30. Peschel, A., et al. 1999. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J. Biol. Chem. 274:8405-8410.
31. Pestka, S. 1974. The use of inhibitors in studies on protein synthesis. Methods Enzymol. 30:261-282.
32. Pini, A., et al. 2005. Antimicrobial activity of novel dendrimeric peptides obtained by phage display selection and rational modification. Antimicrob. Agents Chemother. 49:2665-2672.
33. Pothoulakis, C., et al. 1996. Rabbit sucrase-isomaltase contains a functional intestinal receptor for Clostridium difficile toxin A. J. Clin. Invest. 98:641-649. (Pubitemid 26349168)
34. Pothoulakis, C., and J. T. LaMont. 1993. Clostridium difficile colitis and diarrhea. Gastroenterol. Clin. North Am. 22:623-637.
35. Pothoulakis, C., and J. T. Lamont. 2001. Microbes and microbial toxins: paradigms for microbial-mucosal interactions. II. The integrated response of the intestine to Clostridium difficile toxins. Am. J. Physiol. Gastrointest. Liver Physiol. 280:G178-G183.
36. Pothoulakis, C., G. Triadafilopoulos, M. Clark, C. Franzblau, and J. T. LaMont. 1986. Clostridium difficile cytotoxin inhibits protein synthesis in fibroblasts and intestinal mucosa. Gastroenterology 91:1147-1153.
37. Schumacher, T. N., et al. 1996. Identification of D-peptide ligands through mirror-image phage display. Science 271:1854-1857.
38. Serror, P., T. Sasaki, S. Dusko Ehrlich, and E. Maguin. 2002. Electrotransformation of Lactobacillus delbrueckii subsp. bulgaricus and L. delbrueckii subsp. lactis with various plasmids. Appl. Environ. Microbiol. 68:46-52. (Pubitemid 34031161)
39. Slatore, C. G., and S. A. Tilles. 2004. Sulfonamide hypersensitivity. Immunol. Allergy Clin. North Am. 24:477-490, vii.
40. Soscia, S. J., et al. 2010. The Alzheimer's disease-associated amyloid betaprotein is an antimicrobial peptide. PLoS One 5:e9505.
41. Starner, T. D., W. E. Swords, M. A. Apicella, and P. B. McCray, Jr. 2002. Susceptibility of nontypeable Haemophilus influenzae to human beta-defensins is influenced by lipooligosaccharide acylation. Infect. Immun. 70: 5287-5289.
42. Sullivan, A., and C. E. Nord. 2002. The place of probiotics in human intestinal infections. Int. J. Antimicrob. Agents 20:313-319.
43. Teasley, D. G., et al. 1983. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet ii:1043-1046.
44. Thevissen, K., R. W. Osborn, D. P. Acland, and W. F. Broekaert. 2000. Specific binding sites for an antifungal plant defensin from Dahlia (Dahlia merckii) on fungal cells are required for antifungal activity. Mol. Plant Microbe Interact. 13:54-61.
45. Tran, A. X., et al. 2005. Resistance to the antimicrobial peptide polymyxin requires myristoylation of Escherichia coli and Salmonella typhimurium lipid A. J. Biol. Chem. 280:28186-28194. (Pubitemid 41105714)
46. Trejo, F. M., J. Minnaard, P. F. Perez, and G. L. De Antoni. 2006. Inhibition of Clostridium difficile growth and adhesion to enterocytes by Bifidobacterium supernatants. Anaerobe 12:186-193.
47. Van Regenmortel, M. H., and S. Muller. 1998. D-peptides as immunogens and diagnostic reagents. Curr. Opin. Biotechnol. 9:377-382.
48. Varkey, J., and R. Nagaraj. 2005. Antibacterial activity of human neutrophil defensin HNP-1 analogs without cysteines. Antimicrob. Agents Chemother. 49:4561-4566.
49. Vesga, O., M. Agudelo, B. E. Salazar, C. A. Rodriguez, and A. F. Zuluaga. 2010. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob. Agents Chemother. 54:3271-3279.
50. Warny, M., et al. 2000. p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J. Clin. Invest. 105:1147-1156.
51. Werle, M., A. Makhlof, and H. Takeuchi. 2009. Oral protein delivery: a patent review of academic and industrial approaches. Recent Pat. Drug Deliv. Formul. 3:94-104.